Introduction

Relenza is an oral inhalant that has been developed by Glaxo Wellcome to combat the flu. A recent study has demonstrated Relenza to be effective in preventing the flu, providing an alternative to the current flu vaccines. Glaxo plans to submit a separate application for this indication.

How It Works

Relenza inhibits viral neuraminidase. This enzyme is an essential component in the replication of both type A and B viruses, strains of symptomatic influenza. The affected sites of the viral neuraminidase are conserved so the antiviral action is not influenced by antigenic changes.

Clinical Tips and Trial Results

The use of Relenza as a preventative agent against influenza has some advantages. Once inhaled, the drug immediately takes effect. Also, Relenza is not specific to a particular strain of influenza. A possible disadvantage of the drug is that daily use is required during the time period when a patient wishes to avoid infection.

A randomized, double-blind, placebo-controlled study was conducted at two sites during the flu season. The trial included 1107 patients, and the mean age was 29 years. The participants were required to inhale 10 mg of Relenza or placebo per day for a four-week period. Laboratory-confirmed clinical influenza was defined as documented infection with two or more of the following symptoms recorded concomitantly on three or more consecutive days: cough, headache, sore throat, myalgia, feverishness, or a temperature above 37.8 deg-C. Relenza was prevented laboratory-confirmed clinical influenza in 67% (95% confidence interval [CI], 39%-83%; p-value vs. placebo < 0.001). It was 84% efficacious (95% CI, 55%-94%; p-value vs. placebo = 0.001) in preventing laboratory- confirmed clinical influenza with fever. There were no adverse events recorded in the Relenza group that differed from those in the placebo group. The results of this study provide evidence that Relenza is safe and effective in preventing influenza in healthy adults.

What the Patient Should Know

Use of Relenza has not been associated with any serious adverse events.

RELENZA significantly reduces both theduration of the disease and the severity of the symptoms

RELENZA shortens the duration of the illness by up to 2.5 days

In clinical trials RELENZA significantly improved symptoms such as headache, sore throat, fever, muscle aches, cough, weakness and loss of appetite Symptoms improve within 48hrs of starting the medication

RELENZA is very well tolerated with a safety profile equivalent to placebo

 RELENZA is indicated for the treatment of influenza infection in adultsand children aged 12 years and older

Treatment is most effective when commenced within 48hours of the first sign of symptoms